What is the real market size of the cell therapy market?
Download our beautiful pitch about the cell therapy market
In our cell therapy market deck, you will find everything you need to understand the market
The cell therapy market stands at approximately $6-7 billion in 2026, driven primarily by CAR-T therapies that now generate over $4 billion in annual revenue.
Seven FDA-approved CAR-T products treat blood cancers today, while a pipeline of 1,580+ clinical trials signals rapid expansion into solid tumors and broader applications.
Growth projections range from 17-40% annually through 2030-2034, depending on how quickly the industry conquers manufacturing challenges and scales beyond current autologous approaches.
And if you want to better understand this new industry, you can download our pitch covering the cell therapy market.
Insights
- CAR-T therapies hold 65-75% of total cell therapy market revenue in 2026, with anti-BCMA products targeting multiple myeloma growing fastest at 24% annual growth.
- The top two companies (Gilead and Bristol Myers Squibb) control over 70% of approved CAR-T market share, creating a highly concentrated competitive landscape.
- Autologous therapies dominate with 90-91% market share, but allogeneic platforms are growing 22-27% annually as the industry shifts toward off-the-shelf products.
- Manufacturing costs range from $120,000-$300,000 per dose today, but industry leaders target reductions below $100,000 to enable broader patient access.
- Asia-Pacific contract manufacturers are positioned to supply 40% of global cell therapy output by 2028, reshaping the industry's geographic footprint.
- TIL (tumor-infiltrating lymphocyte) therapies represent only 4-5% of current market but are growing 28-40% annually, the fastest of any modality.
- CAR-T therapies have a 17% chance of FDA approval from Phase 1 versus 5.3% for average oncology drugs, offering builders better odds.
- Manufacturing batch failure rates of 10-20% and requirements of 200 human hours per batch create clear automation opportunities for entrepreneurs.
- The United States commands 38-42% market share with Medicare reimbursement reaching $314,176 per CAR-T treatment in fiscal year 2026.
- Cell and gene therapy venture capital funding dropped 83% from $8.2 billion in 2021 to $1.4 billion in 2024, creating favorable entry valuations.
- Only 35% of initiated CAR-T clinical trials progress beyond Phase 2, highlighting the importance of selecting differentiated targets and patient populations.
How do we define the cell therapy market?
We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including both approved products and major late-stage pipeline therapies.
We include living-cell products such as CAR-T, other engineered immune cells, and non-oncology cell-based drugs, along with their direct clinical use and revenue.
We exclude procedures like standard stem-cell transplants, simple minimally manipulated cell preparations used in surgery, and generic tools or equipment that are not specific to these therapies.
We also use this definition when we make and update our pitch covering everything there is to know about the cell therapy market
In our cell therapy market deck, we will give you useful market maps and grids
What is the size of the cell therapy market in 2026?
What results can we find on the internet?
As you probably know already, many firms regularly publish (sometimes conflicting) estimates of the cell therapy market size, using different definitions, scopes, and years.
We have consolidated their results here. We will use it, among other things, to derive a single, reasonable estimate of the market size.
| Company | Market Size (USD) | Year | Definition vs. Ours |
|---|---|---|---|
| Grand View Research | $5.8-6.0B | 2024-25 | Similar scope focusing on therapeutic cell products. Excludes manufacturing equipment but may include some stem cell transplants. |
| Fortune Business Insights | $8.88B | 2025 | Broader definition including all cell-based therapies. May include adjacent services beyond our core therapeutic focus. |
| Mordor Intelligence | $5.58B | 2025 | Very well aligned covering viable human cells. Excludes gene-only vectors matching our definition closely. |
| Precedence Research | $7.43B | 2025 | Slightly broader including full range of cell sources. Covers therapeutic applications similar to our scope. |
| IMARC Group | $18.0B | 2025 | Much broader likely including stem cell banking services. Includes transplant services beyond our therapeutic drug definition. |
| Straits Research | $6.86B | 2025 | Well-aligned covering therapeutic cell products only. Matches our focus on cell-based drugs. |
| Transparency Market Research | $5.8-6.0B | 2024 | Well-aligned with oncology dominating around 70% of scope. Focuses on therapeutic applications like our definition. |
| Allied Market Research | $15-25B | 2024-26 | Broader with aggressive growth assumptions included. Likely includes adjacent markets and research applications. |
| Emergen Research | $6.4-7.5B | 2024-25 | Similar focusing on therapeutic cell products. Matches our definition of cell-based drugs. |
| Coherent Market Insights | $2.83B | 2025 | Narrower likely covering approved commercial products only. Excludes late-stage pipeline therapies we include. |
| Vantage Market Research | $14-16B | 2024-25 | Broader including research applications and tools. Goes beyond our therapeutic drug focus. |
| Data Bridge Market Research | $21B | 2024 | Similar therapeutic scope but shows reporting inconsistency. Estimate appears inflated compared to verifiable company revenues. |
What can we conclude, then?
The most reliable consensus for the cell therapy market in 2026 sits at $5.5-7.0 billion when we focus on therapeutic cell-based drugs.
Mordor Intelligence ($5.58B) and Straits Research ($6.86B) align most closely with our definition, excluding stem cell banking and research tools.
This is our first estimate, we will refine further using bottom-up calculations and verifiable company revenue data.
In our cell therapy market deck, we have collected signals proving this market is hot right now
What if we try to make our own estimate?
We don't have to rely only on external analyses to estimate market size.
We will try to build a first-principles, bottom-up calculation, then run a few sanity checks to see whether we can reliably estimate the size of the cell therapy market.
Useful data about the cell therapy market
Here is some useful and reliable data we have collected, they will help us estimate the size of the cell therapy market:
- Seven FDA-approved CAR-T therapies in the US as of November 2024 (FDA)
- Gilead Yescarta generated $1.6 billion revenue in 2024 with 5% year-over-year growth (Gilead)
- Gilead Tecartus generated $403 million revenue in 2024 with 9% year-over-year growth (Gilead)
- Bristol Myers Squibb Breyanzi generated $747 million revenue in 2024, up 105% from 2023 (BMS)
- Bristol Myers Squibb Abecma generated $406 million revenue in 2024, down 14% from 2023 (Bullfincher)
- Johnson & Johnson Carvykti generated $963 million revenue in 2024 approaching blockbuster status (Visible Alpha)
- Novartis Kymriah generated $108 million quarterly revenue in Q4 2024, down 10% year-over-year (Novartis)
- CAR-T therapy list prices range from $373,000 to $633,000 per treatment (HHS ASPE)
- More than 9,000 patients treated globally with Carvykti through late 2025 (J&J)
- 311 FACT-accredited CAR-T treatment centers in the US as of July 2024 (Targeted Oncology)
- 1,580 CAR-T clinical trials registered on ClinicalTrials.gov as of April 2024 (Frontiers in Immunology)
- Medicare CAR-T inpatient reimbursement increased from $269,139 in FY2025 to $314,176 in FY2026 (AJMC)
- Total CAR-T treatment cost reaches $700,000-$1 million per patient including hospitalization (ZS Associates)
- TIL therapy market valued at $0.3 billion in 2025 with first FDA approval in February 2024 (Yahoo Finance)
- TCR-T therapy market valued at $342 million in 2024 with one approved product Tecelra (Roots Analysis)
- NK cell therapy market valued between $340 million and $2.1 billion in 2024 with no FDA approvals yet (Precedence Research)
- MSC therapy market valued between $80.95 million and $1.08 billion in 2024 (Nova One Advisor)
- Six CAR-T therapies approved in the EU covering major markets (EMA)
- United States commands 38-42% of global cell therapy market share (Global Growth Insights)
- Asia-Pacific region represents 21% of market with 14-24% annual growth rate (Global Growth Insights)
Method and calculation to get the size of the cell therapy market
Let's start with the verified CAR-T product revenues from publicly traded companies in 2024.
Gilead's Yescarta and Tecartus combined for $2.0 billion.
Bristol Myers Squibb's Breyanzi and Abecma combined for $1.15 billion.
Johnson & Johnson's Carvykti added $963 million.
Novartis Kymriah generated approximately $432 million annually (based on Q4 quarterly revenue of $108 million).
These five disclosed products total approximately $4.5 billion for 2024.
Two additional FDA-approved CAR-T products exist: Teclistamab and Aucatzyl (approved November 2024).
Aucatzyl launched too recently for significant 2024 revenue.
Estimating conservatively, undisclosed CAR-T products likely contributed $200-300 million in 2024.
This brings total CAR-T revenue to approximately $4.7-4.8 billion for 2024.
CAR-T therapies represent approximately 65-75% of the total cell therapy market based on market research consensus.
Dividing $4.7 billion by 70% (midpoint) yields a total market of approximately $6.7 billion for 2024.
Non-CAR-T therapies add meaningful revenue: TIL therapies ($300 million), TCR-T therapies ($342 million), and MSC therapies ($500-800 million midpoint).
NK cell therapies remain largely pre-commercial with minimal revenue.
These non-CAR-T segments total approximately $1.1-1.4 billion.
Adding CAR-T ($4.7-4.8B) and non-CAR-T ($1.1-1.4B) segments yields $5.8-6.2 billion for 2024.
Applying modest 15-20% growth from 2024 to 2026 gives us $6.7-7.4 billion for 2026.
This calculation accounts for both approved products and late-stage pipeline therapies entering commercial scale.
Sanity checks
The United States represents 38-42% of global market share according to multiple sources.
If US market is $2.8 billion (42% of $6.7B), this implies roughly 6,000-7,000 annual CAR-T treatments at average $400,000 list price.
With 311 FACT-accredited treatment centers in the US, this averages 19-23 treatments per center annually.
This seems reasonable given that many centers are still ramping capacity and not all centers treat equal volumes.
Gilead's Amsterdam facility alone can produce 4,000 Yescarta doses annually.
Global treatment volumes of 10,000-15,000 patients annually align with disclosed Carvykti data (9,000+ cumulative patients).
At $450,000 average list price, 15,000 global treatments would generate $6.75 billion.
This matches our estimate closely when accounting for discounts and non-CAR-T therapies.
Medicare reimbursement increased 17% from $269,139 to $314,176 between FY2025 and FY2026.
This signals growing payer acceptance and supports market expansion projections.
What's our final guess then?
Based on verifiable company revenues and bottom-up calculations, we estimate the cell therapy market at $6-7 billion in 2026.
This aligns with the most credible external research firms (Mordor Intelligence, Straits Research) that share our therapeutic focus.
The cell therapy market in 2026 is similar in size to the global insulin pump market ($6.5 billion) and the immunotherapy drug market segment for melanoma ($7.2 billion).
It's roughly half the size of the global CRISPR technology market ($12 billion) and one-tenth the size of the broader oncology drug market ($200+ billion).
CAR-T products dominate with $4.8-5.2 billion in 2026 revenue, while emerging modalities (TIL, TCR-T, NK cells) contribute $1.2-1.8 billion.
The market concentration is striking: Gilead and Bristol Myers Squibb control over 70% of approved CAR-T revenue.
In our cell therapy market deck, we provide the data and the context to understand it
Is the cell therapy market mature, competitive, fragmented?
The maturity score of the cell therapy market in 2026 is 35/100
The cell therapy market in 2026 remains in early growth phase rather than maturity.
Only seven CAR-T products have FDA approval, with the first approval (Kymriah) coming just in 2017.
The massive pipeline of 1,580 clinical trials indicates the market is far from saturation.
Most trials target blood cancers, while solid tumors (representing 90% of cancer cases) remain largely unaddressed.
Manufacturing processes still require 200 human hours per batch with 10-20% failure rates.
This inefficiency signals significant room for optimization and scaling.
Regulatory frameworks continue evolving, with Medicare reimbursement structures adjusting annually.
The 17% increase in Medicare CAR-T reimbursement from FY2025 to FY2026 shows policy is still catching up to innovation.
The competitiveness score of the cell therapy market in 2026 is 75/100
The cell therapy market in 2026 is highly competitive despite its early stage.
Two companies (Gilead and Bristol Myers Squibb) control over 70% of approved CAR-T market share, creating intense rivalry.
Breyanzi grew 105% year-over-year in 2024 while Abecma declined 14%, showing direct competition for multiple myeloma patients.
Each percentage point of market share represents tens of millions in revenue given $400,000+ pricing.
The pipeline intensity is extraordinary with 1,580 CAR-T trials and hundreds of companies pursuing cell therapy programs.
Venture funding collapsed 83% from 2021 to 2024, forcing companies to compete aggressively for limited capital.
Manufacturing capacity races ahead of demand, with growth outpacing clinical trials by more than 2-to-1 from 2019-2024.
This overcapacity will intensify price pressure and competition for patients.
The fragmentation score of the cell therapy market in 2026 is 40/100
The cell therapy market in 2026 shows moderate fragmentation with clear consolidation trends.
While hundreds of companies participate in development, commercial revenue concentrates heavily in two players.
The approved CAR-T segment is highly concentrated, but emerging modalities (TIL, TCR-T, NK cells) remain fragmented.
No single company dominates tumor-infiltrating lymphocyte therapies despite AMTAGVI's first approval in February 2024.
Geographic fragmentation persists with US (38-42%), Europe (20-29%), and Asia-Pacific (21%) each requiring different regulatory and reimbursement strategies.
Asia-Pacific manufacturing capabilities are dispersed across South Korea, China, and Japan with no dominant regional player.
The 2025 M&A activity ($65 billion in deal value) signals ongoing consolidation that will reduce fragmentation.
Smaller companies with differentiated platforms become acquisition targets for established pharmaceutical companies seeking cell therapy capabilities.
How much bigger will the cell therapy market be in 10 years?
What are the different forecasts for the growth rate of cell therapy market?
One more time, let's check what other market research firms have to say.
| Company | CAGR (%) | Until Year | Adjustments for Our Definition |
|---|---|---|---|
| Grand View Research | 22.66% | 2030 | Aligns well with our therapeutic definition. May include some stem cell transplants requiring slight downward adjustment. Reasonable for CAR-T focused growth. |
| Fortune Business Insights | 40.15% | 2032 | High growth driven by CAR-T focus closely aligned with our definition. Minimal adjustment needed as scope matches therapeutic cell products. Assumes aggressive solid tumor penetration. |
| Mordor Intelligence | 17.05% | 2030 | Good fit with conservative assumptions. May exclude early-stage pipeline therapies we include. Likely underestimates emerging modality growth. |
| Markets and Markets | 39.6% | 2029 | CAR-T cell specific directly aligns with engineered immune cells. No adjustment needed for scope. Reflects optimistic clinical success assumptions. |
| Precedence Research | 22.96% | 2034 | Includes stem cells requiring slight downward adjustment. Exclude transplant overlap to match our definition. Core therapeutic segment aligns well. |
| Allied Market Research | 25.6% | 2027 | Broader scope including stem cell banking. Apply 15-20% downward adjustment for non-therapeutic segments. Therapeutic core matches our focus. |
| Emergen Research | 16.3% | 2032 | Conservative estimate may exclude emerging non-oncology therapies. Could underestimate TIL and NK cell growth. Otherwise well-aligned with definition. |
| Transparency Market Research | 20.8% | 2034 | Aligns reasonably with therapeutic focus. May include broader regenerative medicine scope. Minimal adjustment for oncology-focused segment. |
| Straits Research | 22.12% | 2033 | Similar scope to ours covering therapeutic products. Minimal adjustment needed. Well-balanced growth assumptions. |
| IMARC Group | 14.55% | 2034 | Lower CAGR reflects conservative therapeutic definition. Excludes some pipeline therapies. May underestimate emerging modality impact. |
| Data Bridge Market Research | 19.2% | 2032 | Good fit for therapeutic products. May include some R&D tools in segmentation. Core therapeutic market well-aligned. |
| BCC Research | 26.4% | 2028 | Combined cell and gene therapy requiring separation. Gene therapy portion (approximately 40%) needs exclusion. Cell therapy portion aligns well. |
What can we conclude about the growth rate of the cell therapy market?
The cell therapy market shows a wide range of projected growth rates from 14.55% to 40.15% annually depending on scope and assumptions.
For our therapeutic-focused definition, a compound annual growth rate of 20-24% through 2030 appears most reasonable based on credible sources.
CAR-T specific segments should grow faster at 30-40% annually as they expand into earlier treatment lines and solid tumors.
Emerging modalities (TIL, NK cells) may grow even faster from smaller bases but contribute less absolute revenue.
Using a 22% CAGR (median of best-aligned sources), the cell therapy market would reach approximately $17 billion by 2030.
This represents a 2.5x increase from the 2026 baseline of $6.5-7 billion.
By 2036 (10 years from now), applying the same 22% CAGR yields a cell therapy market of approximately $48 billion.
This represents a 7x multiple from 2026, though growth rates will likely moderate as the market matures.
More conservative scenarios using 18% CAGR reach $13 billion by 2030 and $35 billion by 2036.
Optimistic scenarios using 28% CAGR reach $24 billion by 2030 and $77 billion by 2036.
The realistic case of $48 billion by 2036 would make the cell therapy market roughly equivalent to today's global CAR-T and checkpoint inhibitor markets combined.
This assumes successful penetration into solid tumors, manufacturing cost reductions below $100,000 per dose, and allogeneic platforms capturing 30-40% market share.
And if you're curious about what's happening in this (really interesting) market, we publish a quarterly update on the activity in the cell therapy market here. We also have a monthly update here.
In our cell therapy market deck, we dentify risks investors and builders need to be aware of
What is the projected CAGR for the cell therapy market?
At New Market Pitch, we like it when the information is clear and easy to digest, as you will see in the pitch about the cell therapy market. That's also why we have made this clear summary table.
| Year | Worst Case (17% CAGR) | Realistic (22% CAGR) | Best Case (28% CAGR) |
|---|---|---|---|
| 2027 | $7.8B | $8.1B | $8.5B |
| 2028 | $9.1B | $9.9B | $10.9B |
| 2029 | $10.7B | $12.1B | $13.9B |
| 2030 | $12.5B | $14.7B | $17.8B |
| 2031 | $14.6B | $18.0B | $22.8B |
| 2032 | $17.1B | $21.9B | $29.2B |
| 2033 | $20.0B | $26.7B | $37.4B |
| 2034 | $23.4B | $32.6B | $47.8B |
| 2035 | $27.4B | $39.8B | $61.2B |
| 2036 | $32.0B | $48.5B | $78.4B |
What would it take for the cell therapy market to be worth $80 billion?
Reaching $80 billion in the cell therapy market by 2036 requires three fundamental breakthroughs beyond incremental improvements.
First, CAR-T and TIL therapies must successfully penetrate solid tumors, which represent 90% of cancer cases but remain largely untreated by cell therapies today.
Manufacturing costs must drop below $100,000 per dose from current $120,000-$300,000 levels through automation and closed-system platforms.
This cost reduction enables broader patient access beyond current Medicare-insured populations and opens middle-income country markets.
Allogeneic (off-the-shelf) platforms must capture 40-50% market share versus today's 9-10%, eliminating the 4-6 week manufacturing delays inherent in autologous therapies.
The 542 allogeneic CAR-T agents currently in development signal industry commitment, but commercial success remains unproven.
Treatment center infrastructure must expand beyond the current 311 US facilities to serve 1,000+ global centers with standardized protocols.
The 51% of firms experiencing critical manufacturing staff shortages must resolve through accelerated training programs reducing the current 6-12 month timeline.
Non-oncology applications (cardiac repair, diabetes, neurological disorders) must reach commercial viability and capture 35-40% of total cell therapy market revenue.
Current non-oncology therapies represent only 25-35% and remain mostly experimental without large revenue-generating products.
Regulatory frameworks must enable accelerated approvals based on surrogate endpoints rather than requiring long-term survival data for each indication.
The current 17% Phase 1 to approval success rate for CAR-T therapies must be maintained or improved despite expanding into more difficult indications.
Asia-Pacific manufacturing dominance (projected 40% of global output by 2028) must translate into local market development rather than just contract manufacturing.
China's 500+ clinical trials and South Korea's 53% APAC market share position the region for both supply and demand growth.
In our cell therapy market deck, we answer all the common questions from investors and entrepreneurs
Where is the money in the cell therapy market?
What are the categories and how much do they generate?
CAR-T therapies dominate the cell therapy market in 2026 with 65-75% of total revenue, approximately $4.3-5.2 billion.
Within CAR-T, anti-CD19 products targeting B-cell malignancies hold 54-65% of revenue, while anti-BCMA products for multiple myeloma capture approximately 30%.
Tumor-infiltrating lymphocyte (TIL) therapies represent 4-5% of the cell therapy market with approximately $300-350 million in revenue.
AMTAGVI's February 2024 approval for metastatic melanoma marks the category's commercial emergence, with over 95% of TIL candidates pursuing autologous approaches.
TCR-T (T-cell receptor) therapies contribute approximately 4-5% of revenue at $340-400 million in 2026.
Tecelra (tebentafusp) for uveal melanoma remains the only approved product, with melanoma accounting for over 95% of current TCR-T applications.
NK (natural killer) cell therapies and MSC (mesenchymal stem cell) therapies combine for approximately 15-20% of the cell therapy market.
NK cell therapies show high potential with 50+ active CAR-NK clinical trials but lack FDA-approved products, limiting current revenue to experimental use.
Non-oncology cell therapies (cardiac, diabetes, neurological) represent the remaining 10-15% of market revenue.
These applications remain largely in clinical development with over 1,200 MSC trials registered globally but limited commercial traction.
Finally, if you really want to understand where is the money, you can check our ranking of the most funded startups in the cell therapy market as well as our list of the most valued startups.
How will it evolve?
CAR-T therapies will likely decline from 70% market share in 2026 to approximately 55-60% by 2030 as other modalities mature.
By 2036, CAR-T could represent 45-50% of the cell therapy market as TIL, NK cells, and non-oncology applications grow faster.
TIL therapies should capture 10-12% market share by 2030 and 15-18% by 2036 as solid tumor applications expand.
The 28-40% CAGR for TIL therapies reflects both base effect and genuine clinical differentiation in melanoma and potentially lung cancer.
NK cell therapies could reach 8-10% market share by 2030 and 15-20% by 2036 once first approvals arrive.
The 62% focus on allogeneic platforms positions NK cells as the leading off-the-shelf category, potentially capturing solid tumor markets where autologous CAR-T struggles.
Non-oncology cell therapies may grow from 15% share in 2026 to 20-25% by 2030 and 25-30% by 2036.
Cardiac repair and diabetes represent the largest opportunities, with musculoskeletal disorders (42% of stem cell applications) providing near-term commercial validation.
Where to spend your energy as an investor or a builder in the cell therapy market then?
Investors should focus on allogeneic platform companies before first major approvals arrive in 2027-2028.
The 542 allogeneic CAR-T agents in development create clear winners and losers, with companies demonstrating consistent manufacturing and early efficacy data commanding premium valuations.
Manufacturing automation and closed-system platforms represent underappreciated opportunities given the 200 human hours per batch and 10-20% failure rates.
Companies reducing manufacturing costs from $200,000+ to sub-$100,000 levels unlock entire new patient populations and geographic markets.
TIL therapy builders should pursue combination approaches with checkpoint inhibitors rather than monotherapy given melanoma's competitive landscape.
Expansion into lung cancer and other solid tumors with high tumor mutational burden offers differentiation from CAR-T's blood cancer focus.
NK cell therapeutic companies with demonstrated cytotoxicity against solid tumors and scalable allogeneic manufacturing represent the highest risk-reward profile.
The absence of FDA approvals creates opportunity for first movers, while the 50+ active trials signal competitive intensity requiring clear differentiation.
And if you're curious about where investors are putting their money right now, we publish a quarterly update on the fundraising activity in the cell therapy market here. We also analyze long-term funding trends in the cell therapy market here.
In our cell therapy market deck, we track adoption trends and shifts in consumer behavior
What is the geographical revenue breakdown for the cell therapy market?
North America
North America commands 45-50% of the cell therapy market in 2026, approximately $3.0-3.5 billion in revenue.
The United States drives this dominance with 311 FACT-accredited CAR-T centers, Medicare reimbursement reaching $314,176 per treatment in FY2026, and all seven FDA-approved CAR-T products available.
By 2030, North America's share will likely decline to 42-45% as other regions develop infrastructure and regulatory frameworks.
By 2036, expect North America to hold 38-42% market share as Asia-Pacific manufacturing capabilities and local markets mature, though absolute revenue will still grow substantially.
Europe
Europe holds 20-29% of the cell therapy market in 2026, approximately $1.4-2.0 billion in revenue.
Germany leads with innovative NUB (Neue Untersuchungs- und Behandlungsmethoden) reimbursement achieving 75% award rates, while the UK's NHS Cancer Drugs Fund provides structured access pathways for six EMA-approved CAR-T therapies.
By 2030, Europe should maintain 22-27% market share as integrated EMA frameworks and point-of-care manufacturing hubs enable faster patient access.
By 2036, Europe will likely hold steady at 20-25% share, with Germany, UK, and France representing core markets while Eastern European adoption remains limited by reimbursement constraints.
Asia-Pacific
Asia-Pacific represents 21% of the cell therapy market in 2026, approximately $1.3-1.5 billion, and shows the fastest regional growth at 14-24% annually.
South Korea dominates with 53% of APAC market share, while China's 500+ clinical trials and 115 cell and gene therapy trials in 2024 (42% increase) signal aggressive development, and Japan's expedited PMDA framework enables rapid approvals.
By 2030, Asia-Pacific should reach 26-30% market share as Chinese domestic approvals accelerate and regional CDMO investments exceed $5 billion.
By 2036, expect Asia-Pacific to command 32-36% of the cell therapy market, potentially rivaling North America, driven by the region's projected 40% share of global manufacturing output by 2028 and expanding middle-class populations.
Latin America
Latin America holds approximately 1% of the cell therapy market in 2026, roughly $60-70 million in revenue.
Brazil leads regional development with Cellavita's expansion and established stem cell programs, while Mexico conducts 50+ trials but lacks commercial infrastructure for cell therapy manufacturing and distribution.
By 2030, Latin America could reach 2-3% market share as Brazil and Mexico develop national reimbursement frameworks.
By 2036, expect 3-5% market share if regulatory harmonization across MERCOSUR enables regional clinical trial efficiency and cross-border patient access expands from current limitations.
Middle East and Africa
Middle East and Africa combined hold approximately 8% of the cell therapy market in 2026, roughly $480-560 million.
Saudi Arabia drives Middle Eastern growth with $50.4 billion healthcare budget allocations, while South Africa leads regional stem cell initiatives and the Africa Health Organisation launched gene-editing therapy for sickle cell disease in April 2025.
By 2030, expect the region to maintain 7-9% market share as Gulf Cooperation Council countries invest in medical tourism infrastructure.
By 2036, the Middle East and Africa could reach 8-11% share if Saudi Vision 2030 healthcare investments materialize and South African manufacturing hubs serve broader sub-Saharan African markets.
In our cell therapy market deck, we have designed useful charts to give you full market clarity
Related blog posts
- What is the latest news in the cell therapy market?
- Which companies are the most valued in the cell therapy market?
- The latest progress in the cell therapy market
- How funding activity has evolved in the cell therapy market
- What are the key fundraising trends in the cell therapy market?
- Which companies have raised the most funding in the cell therapy market?
- What are the latest funding developments in the cell therapy market?
- A complete list of business models in the cell therapy market
